CSF2 and hepatocellular carcinoma: The genetically engineered oncolytic vaccinia virus expressing GM-CSF (Pexa-Vec or JX-594) induced antitumour immunity and significantly prolonged survival in a dose-dependent manner in HCC clinical trials.4